Recombinant Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)
![Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)](https://www.abcam.com/ps/products/235/ab235578/Images/ab235578-484180-anti-tgf-beta-receptor-i-antibody-epr20923-13-western-blot-wildtype-a549-tgfbr1-knockout-a549-a431-molt4.jpg "Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR20923-13] to TGF beta Receptor I
- Suitable for: IP, WB
- Knockout validated
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-TGF beta Receptor I antibody [EPR20923-13]
See all TGF beta Receptor I primary antibodies -
Description
Rabbit monoclonal [EPR20923-13] to TGF beta Receptor I -
Host species
Rabbit -
Tested applications
Suitable for: IP, WBmore details
Unsuitable for: Flow Cyt (Intra),ICC/IF or IHC -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: MCF7, MCF7 transfected with 100nM siRNA specifically targeting TGF receptor I, MCF7 transfected with 25nM siRNA specifically targeting TGF receptor I, THP-1, RAW264.7, 2.4G2, C6, U-87 MG, SH-SY5Y, Neuro-2a lysates. IP: MCF7 cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR20923-13 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab235578 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IP |
1/30.
|
|
| WB |
1/1000. Predicted molecular weight: 55 kDa.
|
| Notes |
|---|
|
IP
1/30. |
|
WB
1/1000. Predicted molecular weight: 55 kDa. |
Target
-
Function
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta. -
Tissue specificity
Found in all tissues examined, most abundant in placenta and least abundant in brain and heart. -
Involvement in disease
Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients.
Defects in TGFBR1 are the cause of aortic aneurysm familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance. -
Sequence similarities
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
Contains 1 GS domain.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated at basal levels in the absence of ligand binding. Activated by multiple phosphorylation, mainly in the GS region. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 7046 Human
- Entrez Gene: 21812 Mouse
- Entrez Gene: 29591 Rat
- Omim: 190181 Human
- SwissProt: P36897 Human
- SwissProt: Q64729 Mouse
- SwissProt: P80204 Rat
- Unigene: 494622 Human
see all -
Alternative names
- AAT 5 antibody
- AAT5 antibody
- Activin A receptor type II like kinase 53kDa antibody
see all
Images
-
Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)All lanes : Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578) at 1/1000 dilution
Lane 1 : Wild-type A549 cell lysate
Lane 2 : TGFBR1 knockout A549 cell lysate
Lane 3 : A431 cell lysate
Lane 4 : MOLT-4 cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 55 kDa
Observed band size: 40,55 kDa why is the actual band size different from the predicted?False colour image of Western blot: Anti-TGF beta Receptor I antibody [EPR20923-13] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab235578 was shown to bind specifically to TGF beta Receptor I. A band was observed at 40/55 kDa in wild-type A549 cell lysates with no signal observed at this size in TGFBR1 knockout cell line ab277894 (knockout cell lysate ab283082). To generate this image, wild-type and TGFBR1 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
-
![Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)](https://www.abcam.com/ps/products/235/ab235578/Images/ab235578-479462-anti-tgf-receptor-i-antibody-epr2092313-western-blot-adenocarcinoma.jpg)
Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)All lanes : Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578) at 1/1000 dilution
Lane 1 : MCF7 (human breast adenocarcinoma epithelial cell) transfected with scrambled siRNA control whole cell lysate
Lane 2 : MCF7 transfected with 25nM siRNA specifically targeti TGF receptor I whole cell lysate
Lane 3 : MCF7 transfected with 100nM siRNA specifically targeti TGF receptor I whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20000 dilution
Predicted band size: 55 kDa
Observed band size: 55 kDaBlocking and diluting buffer and concentration: 5% NFDM/TBST
Exposure time: 3 minutes
-
![Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)](https://www.abcam.com/ps/products/235/ab235578/Images/ab235578-479463-anti-tgf-receptor-i-antibody-epr2092313-western-blot-leukemia.jpg)
Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)All lanes : Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578) at 1/1000 dilution
Lane 1 : THP-1 (human monocytic leukemia monocyte) whole cell fresh lysate
Lane 2 : THP-1 (human monocytic leukemia monocyte) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/50000 dilution
Predicted band size: 55 kDa
Observed band size: 37,55 kDa why is the actual band size different from the predicted?Blocking and diluting buffer and concentration: 5% NFDM/TBST
Lane1 Lysate was made freshly and used in WB test immediately to minimize protein degradation.
Exposure time: 81 seconds
-
![Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)](https://www.abcam.com/ps/products/235/ab235578/Images/ab235578-479464-anti-tgf-receptor-i-antibody-epr2092313-western-blot-murine.jpg)
Western blot - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)All lanes : Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578) at 1/1000 dilution
Lane 1 : RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate
Lane 2 : 2.4G2 (rat B cell lymphoma B lymphocyte) whole cell lysate
Lane 3 : C6 (rat glial tumor glial cell) whole cell lysate
Lane 4 : U-87 MG (human glioblastoma-astrocytoma epithelial cell) whole cell lysate
Lane 5 : SH-SY5Y (human neuroblastoma epithelial cell) whole cell lysate
Lane 6 : Neuro-2a (mouse neuroblastoma neuroblast) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/50000 dilution
Predicted band size: 55 kDa
Observed band size: 37,55 kDa why is the actual band size different from the predicted?Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Lysate were made freshly and used in WB test immediately to minimize protein degradation.
Exposure time: 3 minutes
-
![Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)](https://www.abcam.com/ps/products/235/ab235578/Images/ab235578-2-Benefits-of-Recombinant-antibodies.jpg)
Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578) -
![Immunoprecipitation - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)](https://www.abcam.com/ps/products/235/ab235578/Images/ab235578-479839-anti-tgf-beta-receptor-i-antibody-epr20923-13-immunoprecipitation.jpg)
Immunoprecipitation - Anti-TGF beta Receptor I antibody [EPR20923-13] (ab235578)TGF beta Receptor I was immunoprecipitated from 0.35 mg MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate 10 µg with ab235578 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab235578 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate 10 μg
Lane 2: ab235578 IP in MCF7 whole cell lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab235578 in MCF7 whole cell lysate
The bands beneath the target band is caused by degradation as demonstrated by WB data.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (1)
ab235578 has been referenced in 1 publication.
- Gao Y et al. HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation. Int J Biol Sci 18:5724-5739 (2022). PubMed: 36263180